VANNI, DANIELE
VANNI, DANIELE
DIPARTIMENTO DI MEDICINA MOLECOLARE
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis
2021-01-01 Trotti, C; Sant'Antonio, E; Vanni, D; Casetti, Ic; Borsani, O; Pietra, D; Ferretti, Vv; Astori, C; Arcaini, L; Rumi, E.
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
2022-01-01 Borsani, Oscar; Bastard, Paul; Rosain, Jérémie; Gervais, Adrian; Sant'Antonio, Emanuela; Vanni, Daniele; Casetti, Ilaria Carola; Pietra, Daniela; Trotti, Chiara; Catricalà, Silvia; Ferretti, Virginia Valeria; Malcovati, Luca; Arcaini, Luca; Casanova, Jean-Laurent; Borghesi, Alessandro; Rumi, Elisa
Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
2022-01-01 Vanni, Daniele; Borsani, Oscar; Nannya, Yasuhito; Sant'Antonio, Emanuela; Trotti, Chiara; Casetti, Ilaria Carola; Pietra, Daniela; Gallì, Anna; Zibellini, Silvia; Ferretti, Virginia Valeria; Malcovati, Luca; Ogawa, Seishi; Arcaini, Luca; Rumi, Elisa
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
2022-01-01 Guglielmelli, P; Ghirardi, A; Carobbio, A; Masciulli, A; Maccari, C; Mora, B; Rumi, E; Triguero, A; Finazzi, Mc; Pettersson, H; Paoli, C; Mannelli, F; Vanni, D; Rambaldi, A; Passamonti, F; Alvarez-Larràn, A; Andreasson, B; Vannucchi, Am; Barbui, T.
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib
2020-01-01 Rumi, E.; Sant'Antonio, E.; Cavalloni, C.; Comolli, G.; Ferretti, V. V.; Cassaniti, I.; Pietra, D.; Trotti, C.; Ciboddo, M.; Furione, M.; Vanni, D.; Casetti, I. C.; Favaron, C.; Baldanti, F.; Arcaini, L.; Cazzola, M.
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
2022-01-01 Barbui, T; Ghirardi, A; Carobbio, A; Masciulli, A; Carioli, G; Rambaldi, A; Finazzi, Mc; Bellini, M; Rumi, E; Vanni, D; Borsani, O; Passamonti, F; Mora, B; Brociner, M; Guglielmelli, P; Paoli, C; Alvarez-Larran, A; Triguero, A; Garrote, M; Pettersson, H; Andréasson, B; Barosi, G; Vannucchi, Am.
Isolated congenital asplenia: An overlooked cause of thrombocytosis
2022-01-01 Borsani, O; Asano, T; Boisson, B; Fraticelli, S; Braschi-Amirfarzan, M; Pietra, D; Casetti, Ic; Vanni, D; Trotti, C; Borghesi, A; Casanova, Jl; Arcaini, L; Rumi, E.
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
2023-01-01 Borsani, O; Ferretti, Vv; Casetti, Ic; Vanni, D; Trotti, C; Pietra, D; De Silvestri, A; Arcaini, L; Rumi, E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis | 1-gen-2021 | Trotti, C; Sant'Antonio, E; Vanni, D; Casetti, Ic; Borsani, O; Pietra, D; Ferretti, Vv; Astori, C; Arcaini, L; Rumi, E. | |
| Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms | 1-gen-2022 | Borsani, Oscar; Bastard, Paul; Rosain, Jérémie; Gervais, Adrian; Sant'Antonio, Emanuela; Vanni, Daniele; Casetti, Ilaria Carola; Pietra, Daniela; Trotti, Chiara; Catricalà, Silvia; Ferretti, Virginia Valeria; Malcovati, Luca; Arcaini, Luca; Casanova, Jean-Laurent; Borghesi, Alessandro; Rumi, Elisa | |
| Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms | 1-gen-2022 | Vanni, Daniele; Borsani, Oscar; Nannya, Yasuhito; Sant'Antonio, Emanuela; Trotti, Chiara; Casetti, Ilaria Carola; Pietra, Daniela; Gallì, Anna; Zibellini, Silvia; Ferretti, Virginia Valeria; Malcovati, Luca; Ogawa, Seishi; Arcaini, Luca; Rumi, Elisa | |
| Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study | 1-gen-2022 | Guglielmelli, P; Ghirardi, A; Carobbio, A; Masciulli, A; Maccari, C; Mora, B; Rumi, E; Triguero, A; Finazzi, Mc; Pettersson, H; Paoli, C; Mannelli, F; Vanni, D; Rambaldi, A; Passamonti, F; Alvarez-Larràn, A; Andreasson, B; Vannucchi, Am; Barbui, T. | |
| Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib | 1-gen-2020 | Rumi, E.; Sant'Antonio, E.; Cavalloni, C.; Comolli, G.; Ferretti, V. V.; Cassaniti, I.; Pietra, D.; Trotti, C.; Ciboddo, M.; Furione, M.; Vanni, D.; Casetti, I. C.; Favaron, C.; Baldanti, F.; Arcaini, L.; Cazzola, M. | |
| Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score | 1-gen-2022 | Barbui, T; Ghirardi, A; Carobbio, A; Masciulli, A; Carioli, G; Rambaldi, A; Finazzi, Mc; Bellini, M; Rumi, E; Vanni, D; Borsani, O; Passamonti, F; Mora, B; Brociner, M; Guglielmelli, P; Paoli, C; Alvarez-Larran, A; Triguero, A; Garrote, M; Pettersson, H; Andréasson, B; Barosi, G; Vannucchi, Am. | |
| Isolated congenital asplenia: An overlooked cause of thrombocytosis | 1-gen-2022 | Borsani, O; Asano, T; Boisson, B; Fraticelli, S; Braschi-Amirfarzan, M; Pietra, D; Casetti, Ic; Vanni, D; Trotti, C; Borghesi, A; Casanova, Jl; Arcaini, L; Rumi, E. | |
| SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms | 1-gen-2023 | Borsani, O; Ferretti, Vv; Casetti, Ic; Vanni, D; Trotti, C; Pietra, D; De Silvestri, A; Arcaini, L; Rumi, E. |